TrialNature communications2018
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Xiujuan Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled ittrialcites it